Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality.

Background: Implementing mammogram screening means that clinicians are seeing many breast cancers that will never develop metastases. The purpose of this study was to identify subgroups of breast cancer patients who did not present events related to long-term breast cancer mortality, taking into account diagnosis at breast screening, absence of palpability and axillary involvement, and genomic analysis with PAM50.

Patients And Methods: To identify them, a retrospective observational study was carried out selecting patients without any palpable tumor and without axillary involvement, and a genomic analysis was performed with PAM50.

Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study.

Purpose: HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as demonstrated in neoadjuvant trials. This study aims to provide real-world evidence on the use and effectiveness of combined pertuzumab, trastuzumab and chemotherapy (CT) in early-stage HER2-positive BC.

Methods: A retrospective, multicentre study was conducted on patients diagnosed with HER2-positive early BC treated with neoadjuvant pertuzumab and trastuzumab plus CT at 13 Spanish sites.

Association between reproductive history, breast cancer subtype, and survival in premenopausal women.

Background And Objective: Reproductive history influences breast cancer risk. We analysed its association with tumour subtype and survival in premenopausal women.

Patients And Methods: Retrospective, observational study of premenopausal women with stage I-III breast carcinoma in the last 20 years.

Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer.

Background And Objective: To identify subgroups with good progress over an extended period, we used diagnostic screening, tumour palpability, tumour phenotype, and node involvement.

Patients And Methods: We identified patients with good progress by means of a descriptive, observational and retrospective study.

Results: Of 746 patients diagnosed with node-negative breast cancer between 2001 and 2015: 110 (14.

Experiences with Prescribing Large Quantities of Systemic Anticancer Therapy Near Death.

The most important decision after diagnosing terminal cancer is whether to provide active therapy or withhold treatment. To analyze the aggressiveness of care by evaluating systemic anticancer therapy (SACT) given near to death, describing this care and identifying factors that determine its use. This involves retrospective observational cohorts study.

Evaluation of non-genomic, clinical risk and survival results in endocrine-sensitive, HER-2 negative, lymph node negative breast cancer.

Background And Objectives: In endocrine-sensitive, HER-2 negative, node negative breast cancer, the presence of a low genomic risk allows treatment with adjuvant endocrine therapy alone, obtaining excellent survival rates. The justification for this study is to show that excellent survival rates are also obtained by treating with adjuvant hormone therapy alone, based on clinical risk assessment.

Patients And Methods: A descriptive, observational and retrospective study was performed between 2006 and 2016 with endocrine-sensitive, HER-2 negative, node negative breast cancer, greater than 1cm or between 0.

Off-label antineoplastic drugs. An effectiveness and safety study.

Objective: The use of antineoplastic medicines in special situations is common in clinical practice; it is strongly regulated and there is little information on its outcomes. We have analysed such use and health outcomes.

Methods: All off-label cases between 2005 and 2015, with any type of cancer and in any stage were included.